Board Change • 8h
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 2 highly experienced directors. Independent Director Richard Huennekens was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Jul 23
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$22m Forecast net loss in 3 years: US$2.9m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company. Buy Or Sell Opportunity • Jul 06
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 19% to US$17.33. The fair value is estimated to be US$14.02, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 35%. Revenue is forecast to grow by 31% in 2 years. Earnings are forecast to grow by 59% in the next 2 years. Tillkännagivande • May 30
NeuroPace, Inc. Announces FDA Approval of ECoG Assistant and Submits Next-Generation Patient Data Management System for FDA Review NeuroPace, Inc. announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. ECoG Assistant is the first in a suite of planned NeuroPace AI tools designed to further support clinical decision making through deeper data insights and more efficient ECoG review. Built on years of proprietary, patient-level brain data captured through the RNS System, ECoG Assistant empowers clinicians to be supported in making faster, more confident treatment decisions. The ECoG Assistant model was developed on 124,450 epileptologist labeled iEEG long-episode records, enabling it to identify ECoGs of Interest using these records. Now, from a single view, physicians can review ECoGs of Interest spanning months using the ECoG Assistant Trends Report and explore timing patterns and potential triggers using the Circadian Pattern Chart. NeuroPace plans to officially debut ECoG Assistant at the American Society for Stereotactic and Functional Neurosurgery (ASSFN) Annual Meeting on May 30th, 2026, where clinicians will experience the new technology firsthand. NeuroPace has also submitted its next-generation Patient Data Management System (PDMS) for FDA review, which is designed to modernize the underlying software infrastructure that supports the RNS System. If approved, this platform is expected to improve reliability and scalability for clinicians and patients and provide a more flexible foundation to support AI-enabled capabilities, including additional workflow tools like the recently approved ECoG Assistant and other future applications. The company currently expects Next-Generation PDMS approval in the second quarter of 2026. Tillkännagivande • May 14
Neuropace, Inc. Revises Earnings Guidance for the Full Year 2026 NeuroPace, Inc. revised earnings guidance for the full year 2026. The company expected total revenue for full year 2026 to be between $99 million and $101 million, up from $98 million to $100 million previously. GAAP loss from operations of $19,500,000 to $20,500,000. Tillkännagivande • Apr 30
NeuroPace, Inc. to Report Q1, 2026 Results on May 12, 2026 NeuroPace, Inc. announced that they will report Q1, 2026 results After-Market on May 12, 2026 Tillkännagivande • Apr 29
NeuroPace, Inc. Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study Results and Nautilus Presentation NeuroPace, Inc. announced a major milestone in its clinical evidence program with the publication of 3-year results from the RNS System Post-Approval Study (PAS) in Neurology, alongside the Company’s recent presentation of 12- and 18-month data from its ongoing NAUTILUS trial at the 2026 American Academy of Neurology Annual Meeting. The published PAS results reinforce the RNS System’s well-established value in drug-resistant focal epilepsy, while the NAUTILUS presentation highlights continued progress in expanding the reach of responsive neurostimulation into idiopathic generalized epilepsy (IGE). The RNS System PAS is the largest FDA-reviewed prospective neuromodulation study for focal drug-resistant epilepsy, enrolling 324 implanted patients across 32 U.S. centers. Published 3-year results demonstrated an 82% median seizure reduction, providing further evidence of the RNS System’s strong and durable clinical benefit in a broad real-world adult focal epilepsy population. NeuroPace recently presented 12- and 18-month data from its ongoing NAUTILUS study evaluating the RNS System as an adjunctive therapy for the treatment of antiseizure medication-resistant idiopathic generalized epilepsy with generalized tonic-clonic (GTC) seizures. 18-month results showed a 77% median reduction in GTC seizures compared with baseline, with rapid and sustained reductions over time. Reductions were also observed across other seizure types, including absence and myoclonic seizures, with reductions in both seizure types exceeding those observed for GTC seizures. The data also showed that injury events declined by approximately 30% following treatment and that the use of a benzodiazepine as a rescue medication for a GTC seizure were 44% lower compared with baseline. The Premarket Approval Supplement (PMA-S) application to the FDA seeking to expand the labeled indication for its RNS System to include patients with antiseizure-medication resistant idiopathic generalized epilepsy with generalized tonic-clonic seizures was submitted to the FDA in December of 2025 and is currently under review. Tillkännagivande • Apr 22
NeuroPace, Inc., Annual General Meeting, Jun 05, 2026 NeuroPace, Inc., Annual General Meeting, Jun 05, 2026. Tillkännagivande • Mar 04
NeuroPace, Inc. Reiterates Earnings Guidance for the first quarter and full year of 2026 NeuroPace, Inc. reiterated earnings guidance for the first quarter and full year of 2026. Total revenue for first quarter 2026 to be between $21 million and $22 million.
The company reiterated total revenue guidance for full year 2026 to be between $98 million and $100 million, representing underlying RNS growth of 20% to 22% compared to full year 2025. Tillkännagivande • Feb 21
NeuroPace, Inc. to Report Q4, 2025 Results on Mar 03, 2026 NeuroPace, Inc. announced that they will report Q4, 2025 results After-Market on Mar 03, 2026 Tillkännagivande • Jan 13
NeuroPace, Inc. Provides Earnings Guidance for the First Quarter and Full Year of Fiscal 2026 NeuroPace, Inc. provided earnings guidance for the first quarter and full year of fiscal 2026. For the quarter, the company expects to be approximately $21 million to $22 million.
For the year, the company anticipates total revenue of $98 million to $100 million, which contemplates growth of 20% to 22% for the underlying core RNS business compared to preliminary unaudited 2025 RNS revenue. Tillkännagivande • Dec 18
NeuroPace, Inc. Files PMA Supplement to FDA Seeking Expanded RNS System Indication for Idiopathic Generalized Epilepsy NeuroPace, Inc. announced that it has filed a Premarket Approval Supplement (PMA-S) application to the U.S. Food and Drug Administration (FDA) seeking to expand the labeled indication for its RNS System to include patients with antiseizure-medication (ASM) resistant idiopathic generalized epilepsy (IGE) with generalized tonic-clonic seizures. The PMA-S is supported by positive preliminary results from the NAUTILUS trial, which demonstrated robust 77% median GTC seizure reduction and a favorable safety profile in this highly refractory patient population at 18 months of therapy. The RNS System has been granted Breakthrough Device Designation for this IGE indication, reflecting the significant unmet clinical need and the potential for the therapy to provide more effective treatment than existing options. Under current FDA guidelines, PMA supplements are typically reviewed within approximately 180 days, although actual review times may vary. Tillkännagivande • Dec 09
Neuropace, Inc. Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy NeuroPace, Inc. announced the presentation at the American Epilepsy Society (AES) meeting of preliminary 18-month safety and effectiveness results from its ongoing NAUTILUS1 trial evaluating the RNS®? System as an adjunctive therapy for the treatment of antiseizure medication (ASM) resistant idiopathic generalized epilepsy (IGE) with generalized tonic-clonic (GTC) seizures. At 18 months of therapy, patients treated with the RNS System experienced a 77% median reduction in GTC seizures compared with baseline (p<0.001). Reductions in GTCs and days without any generalized seizure were rapid and sustained over time. The benefits of treatment were strongly endorsed by physicians and patients with Clinical Global Impression of Change exceeding 80% in both groups at 18 months, underscoring the clinical meaningfulness of the observed benefit. Safety results were consistent with the well-established RNS System profile and demonstrated highly significant (p=<0.0001) outcomes. Tillkännagivande • Dec 02
Neuropace to Highlight Life-Changing Outcomes and Ai-Powered Confident Care At the 2025 American Epilepsy Society (Aes) Annual Meeting NeuroPace, Inc. announced that its RNS System and NeuroPace AI platform will be prominently featured at the 2025 American Epilepsy Society (AES) Annual Meeting in Atlanta, Georgia where NeuroPace will feature new clinical and AI-driven advances that underscore the Company's focus on delivering life-changing outcomes and enabling physicians to provide more confident, data-informed care for people living with epilepsy. Key NeuroPace-related presentations and activities planned for AES include: Post-Approval Study (PAS) Data; New analyses from the RNS System PAS, including additional detail on seizure reduction durability at three years and beyond, and prolonged periods of GTC seizure freedom in many patients. NAUTILUS Trial - 18-month Preliminary Safety and Efficacy Results; Updated data from the NAUTILUS clinical trial, the first and only study to evaluate responsive thalamic stimulation for the treatment of idiopathic generalized epilepsy (IGE), including 18-month safety and efficacy outcomes. Discover How RNS System Therapy Can Strengthen Epilepsy Practice: Saturday, December 6, 2025; Session Focus: Best practices from experienced RNS centers on clinic qualifications, patient selection and operational workflows for building a thriving responsive neuromodulation program. Stimulation with a Strategy: Latest Advances in Neuromodulation; Sunday, December 7, 2025; Session Focus: Evolving strategies in network stimulation for focal epilepsy and how the RNS System is advancing the treatment of epilepsy. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. Tillkännagivande • Oct 22
NeuroPace, Inc. to Report Q3, 2025 Results on Nov 04, 2025 NeuroPace, Inc. announced that they will report Q3, 2025 results After-Market on Nov 04, 2025 Tillkännagivande • Aug 13
NeuroPace, Inc. Increases Earnings Guidance for the Year 2025 NeuroPace, Inc. increased earnings guidance for the year 2025 . For the year, company Increased total revenue guidance between $94 million and $98 million, representing growth of 18% to 23% versus $79.9 million in 2024, up from previous guidance of between $93 million and $97 million. Tillkännagivande • Jul 30
NeuroPace, Inc. to Report Q2, 2025 Results on Aug 12, 2025 NeuroPace, Inc. announced that they will report Q2, 2025 results After-Market on Aug 12, 2025 Tillkännagivande • Jun 25
NeuroPace, Inc. Announces CFO Changes NeuroPace, Inc. announced the appointment of Mr. Patrick F. Williams as Chief Financial Officer, effective June 20, 2025. Ms. Rebecca Kuhn has entered into an agreement with the Company to depart from her CFO role and serve in an advisory role to the Company for a twelve-month period. Mr. Williams joins NeuroPace with over 25 years of financial and operational management experience with public medical device companies. Mr. Williams most recently served as Chief Financial Officer at STAAR Surgical. Prior to STAAR, he initially served as the Chief Financial Officer of Sientra before transitioning to the General Manager of the miraDry® business unit. Prior to Sientra, he was Chief Financial Officer of ZELTIQ, a medical device company that was acquired in 2017. Mr. Williams has also served as Vice President at NuVasive, a spine medical device company, in strategy, finance and investor relations roles. Tillkännagivande • May 28
NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study NeuroPace, Inc. announced the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE). The study successfully met its primary 12-week post-implant safety endpoint, demonstrating a low rate of serious adverse events related to the device and implant procedure, consistent with the established safety profile of the RNS System. The study did not reach statistical significance for the primary effectiveness endpoint in the overall study population, which was to show a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation group. Importantly, however, the data did show a clinically meaningful and highly statistically significant response in the primary effectiveness endpoint within a subgroup of patients with lower baseline frequency of generalized tonic-clonic seizures which represented the majority of trial participants. While the study is not powered to show effectiveness in subgroups, this analysis suggests that there is a therapeutic and clinically meaningful benefit of the RNS System in a substantial subpopulation. Additionally, within the entire trial population, clinically relevant data, including median percent seizure reduction, responder rates and improvement in seizure free days showed numerically robust and clinically meaningful improvements over the first year of treatment and continued in those who have progressed to the second year. Notably, in a more challenging epilepsy syndrome which was studied in an ethical and novel study design for medical devices, preliminary data at one-year illustrates the value of the RNS System technology to individualize patient treatment through programming over time. While a distinct study design, these metrics were favorable and higher than rates observed in the Company’s randomized controlled trial in focal epilepsy that led to FDA approval. In the patients that have completed more than 12 months in the study, preliminary metrics showed continued clinical improvement over time, which aligns with prior findings from the RNS System in the focal epilepsy population, including the FDA-reviewed three-year data from the Company’s Post-Approval Study. The NAUTILUS Study is a prospective, multicenter, randomized, single-blind, sham-stimulation controlled study that enrolled 100 participants, with 87 undergoing implantation of the RNS Neurostimulator and Leads across 23 epilepsy centers within the US. Patients had drug-resistant idiopathic generalized epilepsy with a high burden of generalized tonic-clonic seizures, the most severe and dangerous seizure type. NeuroPace received FDA Breakthrough Device Designation status in 2021 for the potential use of its RNS System to treat IGE. Patients in the NAUTILUS trial continue to participate in the study through the completion of two years after the device implant, with prespecified collection of safety and effectiveness data. The Company plans to submit the full dataset to FDA and for peer-reviewed publication. The Company will engage with the FDA to discuss regulatory pathways based on the data. These discussions may include the possibility of utilizing the overall median seizure reduction data across the full study population, as well as pursuing a more targeted indication focused on patients with lower baseline seizure frequency who may represent a majority of patients with IGE. Tillkännagivande • May 15
NeuroPace, Inc. Revises Earnings Guidance for the Full Year 2025 NeuroPace, Inc. revised earnings guidance for the full year 2025. Increased total revenue guidance for full year 2025 to $93 million to $97 million, representing growth of 16% to 21% versus $79.9 million in 2024. Tillkännagivande • Apr 15
NeuroPace, Inc. to Report Q1, 2025 Results on May 13, 2025 NeuroPace, Inc. announced that they will report Q1, 2025 results After-Market on May 13, 2025 Tillkännagivande • Mar 05
NeuroPace, Inc. Provides Revenue Guidance for the Full Year 2025 NeuroPace, Inc. provided revenue guidance for the full year 2025. For the year, Total revenue anticipated to be in the range of $92 million to $96 million, representing growth of 15% to 20% versus $79.9 million in 2024. Tillkännagivande • Feb 21
NeuroPace, Inc. has completed a Follow-on Equity Offering. NeuroPace, Inc. has completed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 933,500
Price\Range: $8.677022
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 413,988
Transaction Features: At the Market Offering Tillkännagivande • Feb 20
NeuroPace, Inc. to Report Q4, 2024 Results on Mar 04, 2025 NeuroPace, Inc. announced that they will report Q4, 2024 results After-Market on Mar 04, 2025 Tillkännagivande • Feb 04
NeuroPace, Inc., Annual General Meeting, Apr 05, 2025 NeuroPace, Inc., Annual General Meeting, Apr 05, 2025. Tillkännagivande • Jan 29
NeuroPace, Inc. Provides Earnings Guidance for the Year 2025 NeuroPace, Inc. provided earnings guidance for the year 2025. For the year, the company expects revenue of $92 million to $96 million, representing growth of 15.5% to 20.5% versus the midpoint of the expected 2024 revenue range of $79.4 million to $79.9 million. Tillkännagivande • Jan 09
Neuropace, Inc. Appoints Scott Huennekens to Its Board of Directors NeuroPace, Inc. announced the appointment of Scott Huennekens to its Board of Directors, effective January 6, 2025. Mr. Huennekens is a successful executive, entrepreneur, board member and investor in over 20 medical device companies, including more than ten start-up and growth companies with market valuations that have totaled over $6 billion and benefited more than twenty million patients. He currently serves as Chair of the board of directors of Envista Holdings, as Chair of the board of directors of Hyperfine and as an independent director on the QuidelOrtho Corporation board of directors, and has served on several boards of other public companies over the years. Mr. Huennekens previously served as President and Chief Executive Officer of Verb Surgical, an independent surgical technology start-up jointly formed by Google and Johnson & Johnson, from 2015 to 2019. Prior to Verb Surgical, he led Volcano Corporation as its only President and Chief Executive Officer from start-up in 2002 through its IPO in 2006 and then its sale to Philips in 2015. He graduated magna cum laude with a B.S. in Business Administration from the University of Southern California and earned an MBA from the Harvard Business School. Tillkännagivande • Dec 05
NeuroPace, Inc. Announces to Showcase the RNS System at the 2024 American Epilepsy Society Annual Meeting NeuroPace, Inc. announced that the Company will have a substantial presence at the 2024 American Epilepsy Society Annual Meeting (AES 2024). The event is being held at the Los Angeles Convention Center from December 6 - 10, 2024. The RNS System will be featured at booth #2119, where NeuroPace will highlight the proven outcomes of responsive neuromodulation, including 82% seizure reduction at three years and improved quality of life across all domains without the chronic side effects associated with other neuromodulation therapies such as depression, anxiety, memory impairment, sleep disruption and voice alterations. The NeuroPace team will be available in the NeuroPace booth to provide demonstrations, and in the Tech Suite to gather clinician input on next generation technologies. Customers are invited to schedule an appointment to join one of the RNS System demonstrations. Tillkännagivande • Dec 04
NeuroPace, Inc. Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome NeuroPace, Inc. announced completion of enrollment and implant procedures in its feasibility investigational device exemption (IDE) study of the RNS System for the treatment of Lennox-Gastaut Syndrome (LGS), a devastating form of childhood-onset epilepsy characterized by cognitive dysfunction and frequent generalized onset seizures that often lead to injury. The IDE study uses the RNS System, which has demonstrated safety and effectiveness of brain-responsive stimulation for treating medically intractable focal onset seizures in people 18 and older, to evaluate whether brain-responsive neurostimulation can also be used to treat LGS. NeuroPace received a $9.3 millionNational Institutes of Health (NIH) grant through the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative to evaluate its responsive neuromodulation technology in those who suffer from LGS. The IDE study funded by the grant was conducted at six sites and enrolled a total of 20 patients 12 years of age and older with LGS and drug-resistant generalized onset seizures. The study will evaluate the safety and effectiveness of the RNS System in treating seizures associated with LGS. Tillkännagivande • Nov 14
NeuroPace, Inc. Revises Earnings Guidance for the Full Year of 2024 NeuroPace, Inc. revised earnings guidance for the full year of 2024. For the year, the company expects total revenue to be in the range between $78 million and $80 million, representing growth of 19% to 22% over 2023, an increase from the $76 million to $78 million range set last quarter. Tillkännagivande • Nov 05
NeuroPace, Inc. Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy NeuroPace, Inc. announced Food and Drug Administration (FDA) submission of three-year safety and effectiveness data from its prospective Post-Approval Study (PAS) of the RNS System in adults with drug-resistant focal epilepsy. The study enrolled more than three hundred patients from more than thirty leading Level 4 Comprehensive Epilepsy Centers in the United States, making it the largest prospectively enrolled trial in the field of neuromodulation for drug-resistant focal epilepsy. Focal epilepsy, in which seizures originate from specific areas of the brain, is the most common form of drug-resistant epilepsy. It is typically diagnosed in childhood or adolescence and often results in a lifetime of seizures. Further consequences from uncontrolled seizures include poor cognitive outcomes, depression, decreased social interaction with peers, increased seizure frequency, and sudden unexplained death in epilepsy (SUDEP). This RNS System PAS study is a five-year prospective, multicenter study required by FDA to gather additional data on the safety and effectiveness of the RNS System as an adjunctive therapy for adult patients with drug-resistant focal epilepsy. The pre-specified primary effectiveness endpoint is at three years of treatment. The RNS PAS study is planned to continue to a five-year follow-up endpoint as part of the RNS System’s initial FDA approval. Tillkännagivande • Oct 23
NeuroPace, Inc. to Report Q3, 2024 Results on Nov 12, 2024 NeuroPace, Inc. announced that they will report Q3, 2024 results After-Market on Nov 12, 2024 Tillkännagivande • Aug 14
NeuroPace, Inc. Increases Revenue Guidance for 2024 NeuroPace, Inc. increased revenue guidance for 2024. For the year, total revenue to range between $76 million and $78 million, representing growth of 16% to 19% over 2023. Tillkännagivande • Jul 24
NeuroPace, Inc. to Report Q2, 2024 Results on Aug 13, 2024 NeuroPace, Inc. announced that they will report Q2, 2024 results After-Market on Aug 13, 2024 Tillkännagivande • May 10
NeuroPace, Inc. Reaffirms Earnings Guidance for the Year 2024 NeuroPace, Inc. Reaffirmed earnings guidance for the year 2024. For the period, the company expects total revenue to range between $73 million and $77 million, representing growth of 12% to 18% over 2023. Reported Earnings • May 09
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2024 results: US$0.32 loss per share (improved from US$0.41 loss in 1Q 2023). Revenue: US$18.1m (up 25% from 1Q 2023). Net loss: US$8.93m (loss narrowed 14% from 1Q 2023). Revenue exceeded analyst estimates by 4.4%. Earnings per share (EPS) missed analyst estimates by 2.6%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 145% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Breakeven Date Change • May 09
Forecast to breakeven in 2026 The 6 analysts covering NeuroPace expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 16% per year to 2025. The company is expected to make a profit of US$6.00m in 2026. Average annual earnings growth of 49% is required to achieve expected profit on schedule. Tillkännagivande • Apr 23
NeuroPace, Inc., Annual General Meeting, Jun 07, 2024 NeuroPace, Inc., Annual General Meeting, Jun 07, 2024, at 10:30 Pacific Standard Time. Agenda: To discuss elect the board of director’s nominees for class iii directors, uri geiger, rakhi kumar and renee ryan, each to hold office until the 2027 annual meeting of stockholders and until their successor is duly elected and qualified or until their earlier death, resignation, or removal; to ratify the selection of pricewaterhousecoopers llp as the company’s independent registered public accounting firm for the fiscal year ending december 31, 2024; and to conduct any other business properly brought before the meeting. Tillkännagivande • Apr 19
NeuroPace, Inc. to Report Q1, 2024 Results on May 08, 2024 NeuroPace, Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024 Major Estimate Revision • Mar 12
Consensus EPS estimates upgraded to US$1.17 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$1.30 to -US$1.17 per share. Revenue forecast steady at US$75.2m. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target up from US$14.71 to US$16.00. Share price fell 4.2% to US$13.60 over the past week. New Risk • Mar 08
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$33m Forecast net loss in 3 years: US$15m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$15m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (4.7% increase in shares outstanding). Tillkännagivande • Mar 07
NeuroPace, Inc. Provides Earnings Guidance for the Year 2024 NeuroPace, Inc. provided earnings guidance for the year 2024. Total revenue to range between $73 million and $77 million, representing growth of 12% to 18% over 2023. Reported Earnings • Mar 06
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: US$1.28 loss per share (improved from US$1.91 loss in FY 2022). Revenue: US$65.4m (up 44% from FY 2022). Net loss: US$33.0m (loss narrowed 30% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.2%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Breakeven Date Change • Mar 06
Forecast to breakeven in 2026 The 7 analysts covering NeuroPace expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 8.2% per year to 2025. The company is expected to make a profit of US$6.00m in 2026. Average annual earnings growth of 40% is required to achieve expected profit on schedule. New Risk • Feb 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (5.5% increase in shares outstanding). Tillkännagivande • Feb 16
NeuroPace, Inc. to Report Q4, 2023 Results on Mar 05, 2024 NeuroPace, Inc. announced that they will report Q4, 2023 results After-Market on Mar 05, 2024 Tillkännagivande • Feb 08
NeuroPace, Inc Announces Resignation of Irina Ridley as Chief Legal Officer and Corporate Secretary On February 1, 2024, Irina Ridley notified NeuroPace, Inc. that she was resigning from her role as the Company’s Chief Legal Officer and Corporate Secretary and that her last day of employment will be March 6, 2024 (the “Separation Date”). Price Target Changed • Jan 09
Price target increased by 15% to US$10.50 Up from US$9.17, the current price target is an average from 6 analysts. New target price is 15% below last closing price of US$12.35. Stock is up 658% over the past year. The company is forecast to post a net loss per share of US$1.39 next year compared to a net loss per share of US$1.91 last year. Breakeven Date Change • Dec 31
Forecast to breakeven in 2026 The 6 analysts covering NeuroPace expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$6.40m in 2026. Average annual earnings growth of 28% is required to achieve expected profit on schedule. Recent Insider Transactions Derivative • Dec 22
Chief Medical Officer notifies of intention to sell stock Martha Morrell intends to sell 48k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of December. If the sale is conducted around the recent share price of US$9.99, it would amount to US$483k. Since March 2023, Martha's direct individual holding has increased from 14.79k shares to 16.74k. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Tillkännagivande • Dec 21
NeuroPace, Inc. Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study NeuroPace, Inc. announced the completion of the patient enrollment goal in its NAUTILUS pivotal study for the treatment of idiopathic generalized epilepsy (IGE) more than one quarter ahead of schedule. NAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy in idiopathic generalized epilepsy, or IGE, and, if successful, RNS could secure the first device-based indication for generalized epilepsy. 40% of drug-refractory epilepsy patients are diagnosed with generalized epilepsy, and NeuroPace believes that this early patient enrollment milestone is reflective of the excitement amongst patients and clinicians in potentially addressing this significant unmet need with the RNS System. Patients with generalized epilepsy do not need Phase II invasive monitoring and would be able to proceed to RNS System therapy faster, through a noninvasive diagnostic process that could be performed both within and outside of the Comprehensive Epilepsy Center setting. These efforts are part of NeuroPace’s broader focus of expanding access to RNS System therapy to aid in addressing the treatment gap for the 1.2 million drug refractory epilepsy patients in the United States. IGE is the second most common type of epilepsy, after focal onset epilepsy, where seizures originate from various parts of the brain at once. It is typically diagnosed in childhood or adolescence and often results in life-long seizures. Patients with IGE often have seizures that may cause loss of consciousness and commonly experience injuries from seizure-related falls. Further consequences from uncontrolled seizures include poor cognitive outcomes, depression, decreased social interaction with peers, increased seizure frequency, and sudden unexplained death in epilepsy (SUDEP). The NAUTILUS Study received an Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) and is a prospective, multicenter, single-blind randomized, sham stimulation controlled pivotal study designed to demonstrate that the RNS System is safe and effective as an adjunctive therapy for patients aged 12 and older with drug-resistant IGE. NeuroPace received FDA Breakthrough Device Designation status in 2021 for the potential use of its RNS System to treat IGE. The trial requires evaluation of a primary safety endpoint and an effectiveness evaluation 12-months post-implant. If the study achieves its primary endpoints, NeuroPace plans to submit a PMA Supplement and also intends to publish findings in a peer-reviewed medical journal. Recent Insider Transactions Derivative • Dec 08
Chief Medical Officer notifies of intention to sell stock Martha Morrell intends to sell 11k shares in the next 90 days after lodging an Intent To Sell Form on the 6th of December. If the sale is conducted around the recent share price of US$8.16, it would amount to US$90k. Since March 2023, Martha has owned 14.79k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Reported Earnings • Nov 09
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Third quarter 2023 results: US$0.28 loss per share (improved from US$0.48 loss in 3Q 2022). Revenue: US$16.4m (up 47% from 3Q 2022). Net loss: US$7.26m (loss narrowed 38% from 3Q 2022). Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) also surpassed analyst estimates by 31%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. New Risk • Nov 08
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 13% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$32m net loss in 2 years). Shareholders have been diluted in the past year (4.1% increase in shares outstanding). Major Estimate Revision • Nov 07
Consensus estimates of losses per share improve by 12% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from US$60.2m to US$62.9m. EPS estimate increased from -US$1.59 per share to -US$1.40 per share. Medical Equipment industry in the US expected to see average net income growth of 26% next year. Consensus price target of US$8.40 unchanged from last update. Share price rose 4.7% to US$7.07 over the past week. Tillkännagivande • Oct 18
NeuroPace, Inc. to Report Q3, 2023 Results on Nov 06, 2023 NeuroPace, Inc. announced that they will report Q3, 2023 results After-Market on Nov 06, 2023 Price Target Changed • Oct 05
Price target increased by 11% to US$7.80 Up from US$7.00, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of US$7.85. Stock is up 117% over the past year. The company is forecast to post a net loss per share of US$1.59 next year compared to a net loss per share of US$1.91 last year. New Risk • Aug 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$32m net loss in 2 years). Share price has been volatile over the past 3 months (9.7% average weekly change). Shareholders have been diluted in the past year (4.1% increase in shares outstanding). Major Estimate Revision • Aug 15
Consensus revenue estimates increase by 14% The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from US$53.0m to US$60.2m. Forecast losses expected to reduce from -US$1.81 to -US$1.59 per share. Medical Equipment industry in the US expected to see average net income growth of 21% next year. Consensus price target of US$7.00 unchanged from last update. Share price rose 9.8% to US$4.50 over the past week. Tillkännagivande • Aug 10
NeuroPace, Inc. Revises Earnings Guidance for the Full Year 2023 NeuroPace, Inc. revised earnings guidance for the full year 2023. For the year, the company Increased total revenue guidance to range between $59 million and $61 million, representing growth of 30% to 34% over 2022, as compared to prior guidance of between $52 million and $54 million. Reported Earnings • Aug 09
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Second quarter 2023 results: US$0.36 loss per share (improved from US$0.52 loss in 2Q 2022). Revenue: US$16.5m (up 62% from 2Q 2022). Net loss: US$9.12m (loss narrowed 28% from 2Q 2022). Revenue exceeded analyst estimates by 31%. Earnings per share (EPS) also surpassed analyst estimates by 23%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Tillkännagivande • Jul 21
NeuroPace, Inc. to Report Q2, 2023 Results on Aug 08, 2023 NeuroPace, Inc. announced that they will report Q2, 2023 results After-Market on Aug 08, 2023 Tillkännagivande • Jun 30
Neuropace, Inc. Announces Board Member Changes NeuroPace, Inc. announced that on June 27, 2023, Michael Favet resigned from his position as a member of NeuroPace’s board of directors, in each case effective as of July 10, 2023. Mr. Favet will participate in NeuroPace’s Officer Severance Benefit Plan which provides severance and change in control benefits under certain circumstances following termination of employment with NeuroPace. On June 28, 2023, NeuroPace appointed Joel Becker as Chief Executive Officer and as a member of the Board, in each case effective as of the Separation Date. Mr. Becker was appointed as a Class I director, with his term in office expiring upon NeuroPace’s 2025 Annual Meeting of Stockholders. Mr. Becker is not currently expected to serve on any committees of the Board. Mr. Becker, age 55, most recently served as President at Viking North Ventures, a firm providing advisory services to medical technology and healthcare companies and investors, from October 2022 to July 2023, in which role he was responsible for providing advisory, leadership and strategy development services. From April 2019 to October 2022, Mr. Becker served as President of the Cardiac Rhythm Management and Neuromodulation product category of Integer Holdings Corporation, a global medical device company, in which role he was responsible for overseeing commercial and operational strategy and execution. Prior to joining Integer, Mr. Becker served as Chief Executive Officer of Xchange Labs, LLC, a healthcare technology SaaS company that develops connectivity products and services focused on providing caregivers access to patient management data and integration with health plan medication management services, from May 2017 to August 2018, in which role he was responsible for commercial and operational execution. From 2004 to 2016, Mr. Becker served in various leadership roles at St. Jude Medical, a global medical device manufacturer acquired by Abbott Laboratories in 2017, including President, Americas Division, from 2013 to 2016, and President, United States Division, from 2011 to 2013. Mr. Becker earned a B.A. in Business Administration from Augustana College and an M.B. A from the University of Minnesota. 
